Fulcrum Therapeutics, Inc. (FULC)

Market Cap	309.30M
Revenue (ttm)	80.00M
Net Income (ttm)	-510,000
Shares Out	53.98M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	296,162
Open	5.37
Previous Close	5.37
Day's Range	5.37 - 5.82
52-Week Range	2.32 - 10.13
Beta	2.29
Analysts	Hold
Price Target	6.57 (+14.66%)
Earnings Date	May 1, 2025

About FULC

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers drug targets for potential treatment inherited aplastic anemias, such as of diamond-blackfan anemia, shwachman-diamond ...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 18, 2019
• Employees: 45
• Stock Exchange: NASDAQ
• Ticker Symbol: FULC
• Website: https://www.fulcrumtx.com

Financial Performance

In 2024, Fulcrum Therapeutics's revenue was $80.00 million, an increase of 2752.05% compared to the previous year's $2.81 million. Losses were -$9.73 million, -90.01% less than in 2023.

Analyst Forecast

According to 8 analysts, the average rating for FULC stock is "Hold." The 12-month stock price forecast is $6.57, which is an increase of 14.66% from the latest price.

Price Target

$6.57

(14.66% upside)

Analyst Consensus: Hold